Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE: Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.
METHODS: Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORR
RESULTS: At data cutoff, 108 patients with previously treated endometrial carcinoma were enrolled, with a median follow-up of 18.7 months. The ORR
CONCLUSION: Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.
Women & Children
Earle A. Chiles Research Institute
Makker, Vicky; Taylor, Matthew H; Aghajanian, Carol; Oaknin, Ana; Mier, James; Cohn, Allen L; Romeo, Margarita; Bratos, Raquel; Brose, Marcia S; DiSimone, Christopher; Messing, Mark; Stepan, Daniel E; Dutcus, Corina E; Wu, Jane; Schmidt, Emmett V; Orlowski, Robert; Sachdev, Pallavi; Shumaker, Robert; and Casado Herraez, Antonio, "Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer." (2020). Articles, Abstracts, and Reports. 3526.